CORRECTION Open Access

Correction to: Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection: A structured summary of a study protocol for a randomized controlled trial



Javed Akram¹, Shehnoor Azhar^{2*}, Muhammad Shahzad³, Wagas Latif⁴ and Khalid Saeed Khan⁵

Correction to: Trials 21, 702 (2020)

https://doi.org/10.1186/s13063-020-04616-4

Following the publication of the original article [1], we were notified of the below corrections:

- 1- In the Intervention and Comparator section, Phosphate is erroneously mentioned.
- 2- In the Participants section, "Participants of any gender or age group having tested positive" should read "Participants of either gender above 18 years of age".

Author details

¹Vice Chancellor/Professor of Internal Medicine, University of Health Sciences, Lahore, Pakistan. ²Public Health, University of Health Sciences, Lahore, Pakistan. ³Professor of Pharmacology, University of Health Sciences, Lahore, Pakistan. ⁴Data Analyst at University of Health Sciences, Lahore, Pakistan. ⁵Distinguished Investigator at Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.

Published online: 15 February 2022

Reference

 Akram J, et al. Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of hydroxychloroquine, oseltamivir and azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21:702. https://doi.org/10.1186/s13063-020-04616-4.

The original article can be found online at https://doi.org/10.1186/s13063-020-04616-4.

²Public Health, University of Health Sciences, Lahore, Pakistan Full list of author information is available at the end of the article



© The Author(s). 2022 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*} Correspondence: shehnoor.azhar@gmail.com